KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Nat Commun · 2026-Mar-14 · PMID 41826281

Panel B质量警告待 EXE 对齐验证

Progression-free Survival

Fig. 5. Progression-free survival by metastatic disease at baseline. Kaplan–Meier estimate in subgroups with metastatic disease ( A ) and without metastatic disease ( B ), and subgroup analysis ( C ). Source data are provided as a Source data file.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.36
质量通过否
预期曲线2
实际曲线1
X 范围0 – 33
Y 范围0 – 100

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

匹配 15 行
Curve序号X (norm)Y (norm)X (real)Y (real)X (pixel)Y (pixel)
110.00001.00000.0000100.000010929
120.06040.94871.992094.871813939
130.06240.94362.058494.359014040
140.06440.94362.124794.359014140
150.06640.94362.191194.359014240
160.06840.94362.257594.359014340
170.07040.94362.323994.359014440
180.07240.94362.390394.359014540
190.07440.94362.456794.359014640
1100.07650.94362.523194.359014740
1110.07850.94362.589594.359014840
1120.08050.94362.655994.359014940
1130.08250.94362.722394.359015040
1140.08450.94362.788794.359015140
1150.08650.94362.855194.359015240
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-24T15:13:30+00:00